Loading...
Loading...
ALVOW| Name | Value |
|---|---|
| Revenues | 4.4M |
| Cost of Revenue | 28.8M |
| Gross Profit | -24.4M |
| Operating Expense | 68.4M |
| Operating I/L | -92.8M |
| Other Income/Expense | 261.7M |
| Interest Income | 150.9M |
| Pretax | 168.9M |
| Income Tax Expense | -20.5M |
| Net Income/Loss | 189.3M |
Alvotech Holdings SA and its subsidiaries specialize in the development and manufacturing of biosimilars for global markets. By creating high-quality and cost-effective alternatives to existing biologic drugs, the company aims to address the growing demand for affordable biopharmaceuticals. With a focus on biosimilar products, Alvotech generates revenue through the sale and distribution of these pharmaceuticals to healthcare providers, pharmacies, and other stakeholders in the global market.
